Table 1.
Aging | Cancer | |
---|---|---|
DNA Methylation | ||
DNA hypo-methylation | ↑LINE and SINE regions 16–21 | ↑LINE and SINE regions13,19,24–26 |
DNA hyper-methylation | ↑CGIs 20–21, 33, 35 | ↑ CGIs 5,14,34–36 |
Histones modifications | ||
H4K16ac | ↓ in vitro in aged cycling human fibroblasts52 | ↓various cancers55 |
H4K20me3 | ↓ in vitro in aged cycling human fibroblasts52 ↑ in vivo in livers and kidneys of old rats78 ↑ Hutchinson-Gilford Progeria cells77 |
↓various cancers55, 74 ↓ rats model73 |
H3K9ac | ↑ in vitro in aged cycling human fibroblasts52 | ↑ lung cancer81 ↓ breast cancer80 |
H3K4me3 | ↑ in vitro in aged cycling human fibroblasts52 | ↓ breast cancer141 ↑ glioblastoma136, renal cell carcinomas137 |
H3K9me3 | ↓ in vitro in aged cycling human fibroblasts52 | ↑ humans91 ↓ pancreatic carcinomas138 |
H3K27me3 | ↓ Hutchinson-Gilford Progeria cells77 ↓ senescent cells99 |
↑ esophageal squamous cell carcinoma139 ↓ pediatric high-grade gliomas102 |
LncRNA | ||
HOTAIR | ND | ↑ breast114 |
HOTTIP | ND | ↑ liver, leukemia 116, 117 |
CTBP1-AS | ND | ↑ prostate118 |
ANRASSF1 | ND | ↑ breast, prostate119 |
XIST | ↓ senescence122 | ND |
MALAT1 | ↓ senescence122 | ↑ various cancers140 |
SAL-RNA1 | ↓ senescence122 | ND |
ANRIL | ↓ senescence126 | ↑ prostate, leukemia 126–127 |
ND: not determined; Red: reduction of indicated feature; Green: increase of indicated feature